Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5790-5797

  Covington, Paul ^a   Davenport, J Michael ^a   Andrae, David ^a   O'Riordan, William ^b   Liverman, Lisa ^a   McIntyre, Gail ^a   Almenoff, June ^a  

^a Furiex Pharmaceuticals Inc   (United States)

^b ECMC Department of Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JNJ Q2; LINEZOLID; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ABSCESS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATION; CELLULITIS; CHOLECYSTITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SKIN ALLERGY; SUPRAVENTRICULAR TACHYCARDIA; TEMPERATURE; TREATMENT DURATION; TREATMENT RESPONSE; WOUND INFECTION;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 81555200433     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05044-11     Document Type: Article

References (26)

1. Abbanat, D., C. Santoro, and A. S. Lynch. 2010. Activity of a new fluoroquinolone JNJ-Q2 and comparators in an in vitro Staphylococcus aureus biofilm model, poster F1-2092. Abstr. 51st Int. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
2. Acar, J. F., and F. W. Goldstein. 1997. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24(Suppl. 1):S67-S73.
3. Appelbaum, P. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:398-408. (Pubitemid 47498971)
4. Blackwelder, W. C. 1982. Proving the null hypothesis in clinical trials. Control. Clin. Trials 3:345-353. (Pubitemid 13113168)
5. Corey, G. R., and M. Stryjewski. 2011. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin. Infect. Dis. 52(Suppl. 7):S469-S476.
6. Drlica, K., and D. Hooper. 2003. Mechanisms of quinolone action, p. 19-40. In D. C. Hooper and E. Rubinstein (ed.), Quinolone microbiological agents, 3rd ed. ASM Press, Washington, DC.
7. Farrell, D. J., L. C. Liverman, D. J. Biedenbach, and R. N. Jones. 2010. JNJ-Q2: a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains, poster LB-3. Abstr. 48th Annu. Infect. Dis. Soc. Am. Meet. Infectious Diseases Society of America, Arlington, VA.
8. Farrell, D. J., L. C. Liverman, P. R. Rhomberg, and R. N. Jones. 2011. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary (2010) European pathogens isolated from patients with acute bacterial skin and skin-structure infections, poster 1138. 21st Annu. Eur. Congr. Clin. Microbiol. Meet., Milan, Italy. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
9. Fernandez, J., et al. 2010. Efficacy of a new fluoroquinolone (FQ) JNJ-Q2 in murine models of Staphylococcus aureus and Streptococcus pneumoniae infection, poster F1-2093. Abstr. 51st Int. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Food and Drug Administration. 2010. Acute bacterial skin and skin structure infections: developing drugs for treatment. Draft guidance for industry. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov /downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances /UCM071185.pdf.
11. Food and Drug Administration. 2010. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. Anti-Infective Advisory Committee. Briefing document. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov /downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti -InfectiveDrugsAdvisoryCommittee/UCM224656.pdf.
12. Garcia, M., et al. 2010. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303:2260-2264.
13. Hiramatsu, K., et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. (Pubitemid 28036828)
14. Hosmer, D. W., and S. Lemeshow. 1989. Applied logistic regression. John Wiley & Sons, New York, NY.
15. Jones, R. N., R. E. Mendes, and H. S. Sader. 2010. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J. Antimicrob. Chemother. 65:17-31.
16. Liu, C., and A. Bayer. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:285-322.
17. Maltezou, H. C., and H. Giamarellou. 2006. Community-acquired methicillin- resistant Staphylococcus aureus infections. Int. J. Antimicrob. Agents 27:87-96. (Pubitemid 43138839)
18. Moran, G. J. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
19. Morrow, B., et al. 2010. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob. Agents Chemother. 54:1955-1964.
20. Noel, G. J., et al. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44.
21. Rice, L. B. 2006. Antimicrobial resistance in Gram-Positive bacteria. Am. J. Med. 119:S11-S19.
22. Srinivasan, A., J. Dick, and T. Perl. 2002. Vancomycin resistance in staphylococci. Clin. Microbiol. Rev. 15:430-438. (Pubitemid 34761351)
23. Stryjewski, M. E., et al. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607. (Pubitemid 40720810)
24. Tabaqchali, S. 1997. Vancomycin-resistant Staphylococcus aureus: apocalypse now? Lancet 350:1644.
25. Talbot, G., D. Thye, A. Das, and Y. Ge. 2007. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51:3612-3616. (Pubitemid 47519351)
26. Tsiodras, S., et al. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208. (Pubitemid 32718546)